Phase I and Clinical Pharmacology Study of Bevacizumab, Sorafenib, and Low-dose Cyclophosphamide in Children and Young Adults with Refractory/Recurrent Solid Tumors

PURPOSE: To determine the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), pharmacokinetics (PK), and pharmacodynamics (PD) of sorafenib, bevacizumab, and low-dose oral cyclophosphamide in children and young adults with recurrent/refractory solid tumors. PATIENTS AND METHODS: Sorafenib...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Navid, Fariba, Baker, Sharyn D., McCarville, M. Beth, Stewart, Clinton F., Billups, Catherine A., Wu, Jianrong, Davidoff, Andrew M., Spunt, Sheri L., Furman, Wayne L., McGregor, Lisa M., Hu, Shuiying, Panetta, John C., Turner, David, Fofana, Demba, Reddick, Wilburn E., Leung, Wing, Santana, Victor M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2012
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3537913/
https://ncbi.nlm.nih.gov/pubmed/23143218
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-12-1897
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados